-Sinobiopharma to Market the World's First Perindopril in Capsule Form- NANJING, China, April 6 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma", or "the Company") (OTC:SNBP) (BULLETIN BOARD: SNBP) is pleased to announce that it has applied for a single Chinese patent for new drug compounds containing Perindopril, an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension) and heart attack in people with coronary artery disease. Sinobiopharma is the world's first manufacturer and marketer of Perindopril in capsule form. The Company's patent application covers the method of preparation and stability for new drug compounds containing Perindopril. High blood pressure is a leading cause of stroke, heart attack and kidney failure and affects about a billion people worldwide. In China, incidences of cardiovascular and cerebrovascular disease are on rise, costing patients about 300 billion yuan (US$37 billion) in medical expenses each year, of which 30 billion (US$3.7 billion) is spent directly for the treatment of hypertension (source: China's Ministry of Health). "High blood pressure affects nearly one in five Chinese adults during his lifetime (source: State Council of China). The urgency to bring new medicines to market to treat this deadly disease is paramount in China and worldwide," said Sinobiopharma Vice President Xuejun Chen. "As China's first maker of the next generation of Perindopril, Sinobiopharma comes to market with significant competitive advantages including lower API (active pharmaceutical ingredient) costs, an easier-to-swallow formula, greater efficacy and reduced side effects compared to earlier versions of the drug. We look forward to launching the next generation of Perindopril compounds, following confirmation of the standardization of usage, later this year." Perindopril, used alone or in combination with other medications to treat high blood pressure, is the latest generation of a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It supports circulation by preventing the production of chemicals that occur naturally in the body but constrict blood vessels. The Company has received the Drug Certificate for Perindopril raw material (Certificate #2007S00493) from the Chinese State Food and Drug Administration, (SFDA), and is now awaiting GMP Certification. The Company has submitted its application to China's State Intellectual Property Office (SIPO) for a Chinese patent for Perindopril and its new drug compounds and obtained a receiving number (200810242989.1; "New Drug Compounds Containing Perindopril"). Sinobiopharma completed clinical trials for the capsule formulation in September 2007. Sinobiopharma has received approval from the SFDA to manufacture and market its new version of the anti-hypertensive drug, Perindopril, as well as its API. Prior to SFDA approval of Sinobiopharma's version, Servier (France) was the only firm to market Perindopril in China. About Sinobiopharma Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law. DATASOURCE: Sinobiopharma, Inc. CONTACT: Investor Relations of Sinobiopharma, Inc., +1-877-568-0188 Web Site: http://www.sinobiopharma.com/

Copyright